Atossa Therapeutics (ATOS) – Company Press Releases
-
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
-
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
-
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
-
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
-
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
-
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
-
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
-
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
-
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
-
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
-
Atossa Therapeutics Issues Letter to Shareholders
-
Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus
-
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
-
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
-
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
-
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
-
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
-
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
-
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later
-
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
-
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
-
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
-
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
-
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
-
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
-
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
-
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
-
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
-
Atossa Therapeutics Announces $10M Stock Repurchase Program
-
Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
-
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
-
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
-
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
-
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
-
Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
-
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices
-
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”
-
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
-
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
-
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
-
Atossa to Present at the Sidoti Small-Cap Virtual Conference
-
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
-
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen
-
Atossa Therapeutics Issues Letter to Shareholders
-
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
-
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
-
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy
Back to ATOS Stock Lookup
